Related Experiment Videos
Liver transplantation for primary biliary cirrhosis: a long-term pathologic study
Urmila Khettry1, Namrata Anand, Peter N Faul
1Department of Anatomic Pathology, Lahey Clinic Medical Center, 41 Mall Road, Burlington, MA 01805, USA. urmila.khettry@lahey.org
Summary
Recurrent autoimmune liver disease, including primary biliary cirrhosis (PBC) and AILD-NOS, affects 30% of liver transplant recipients. Progression of recurrent disease is linked to graft failure, highlighting the need for long-term monitoring.
Area of Science:
- Hepatology
- Transplantation Immunology
- Gastroenterology
Background:
- Recurrent primary biliary cirrhosis (PBC) post-liver transplantation (LT) is known, but its full spectrum and progression remain unclear.
- Understanding recurrence patterns is crucial for managing long-term outcomes after LT for PBC.
Purpose of the Study:
- To analyze the clinicopathologic features and progression of recurrent autoimmune liver disease after LT for PBC.
- To identify factors associated with recurrence and graft failure in LT recipients with PBC.
Main Methods:
- Retrospective analysis of 43 patients undergoing LT for PBC.
- Detailed review of pre- and post-transplant liver biopsy specimens.
- Clinical data including patient demographics, immunosuppression, and follow-up were analyzed.
Main Results:
- Recurrent autoimmune liver disease (PBC and/or AILD-NOS) was observed in 30% of patients.
- Progressive fibrosis occurred in 46% of patients with recurrence, associated with graft failure.
- Azathioprine use was more frequent in patients without recurrence (P=.01), and shorter follow-up was noted in this group.
Conclusions:
- Recurrent autoimmune liver disease is a significant concern post-LT for PBC, with potential for graft failure.
- Plasmacytosis on biopsy may precede definitive recurrence diagnosis.
- Longer follow-up is needed to fully assess recurrence risk, especially in patients on azathioprine.